[go: up one dir, main page]

MX2021007324A - Terapia oral con acido 6,8-bis-benciltio-octanoico. - Google Patents

Terapia oral con acido 6,8-bis-benciltio-octanoico.

Info

Publication number
MX2021007324A
MX2021007324A MX2021007324A MX2021007324A MX2021007324A MX 2021007324 A MX2021007324 A MX 2021007324A MX 2021007324 A MX2021007324 A MX 2021007324A MX 2021007324 A MX2021007324 A MX 2021007324A MX 2021007324 A MX2021007324 A MX 2021007324A
Authority
MX
Mexico
Prior art keywords
benzylthio
bis
octanoic acid
oral therapy
therapy
Prior art date
Application number
MX2021007324A
Other languages
English (en)
Inventor
Lakmal Boteju
Robert G L Shorr
Timothy S Pardee
Original Assignee
Rafael Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rafael Pharmaceuticals Inc filed Critical Rafael Pharmaceuticals Inc
Publication of MX2021007324A publication Critical patent/MX2021007324A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona métodos y composiciones para tratar una enfermedad o trastorno mediante la administración oral a un paciente que lo necesita de ácido 6,8-bis-benciltio-octanoico o una sal aceptable para uso farmacéutico del mismo, opcionalmente en combinación con un segundo agente terapéutico.
MX2021007324A 2018-12-20 2019-12-20 Terapia oral con acido 6,8-bis-benciltio-octanoico. MX2021007324A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782938P 2018-12-20 2018-12-20
US201962834478P 2019-04-16 2019-04-16
PCT/US2019/067763 WO2020132401A1 (en) 2018-12-20 2019-12-20 Oral therapy using 6,8-bis-benzylthio-octanoic acid

Publications (1)

Publication Number Publication Date
MX2021007324A true MX2021007324A (es) 2021-08-16

Family

ID=71101630

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007324A MX2021007324A (es) 2018-12-20 2019-12-20 Terapia oral con acido 6,8-bis-benciltio-octanoico.

Country Status (11)

Country Link
US (1) US20220040133A1 (es)
EP (1) EP3897606A4 (es)
JP (1) JP2022514084A (es)
KR (1) KR20210105913A (es)
CN (1) CN113543779A (es)
AU (1) AU2019405976A1 (es)
CA (1) CA3121645A1 (es)
IL (1) IL283609A (es)
MX (1) MX2021007324A (es)
TW (1) TW202038930A (es)
WO (1) WO2020132401A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3200914A1 (en) * 2020-12-03 2022-06-09 Vidyanath CHAUDHARY Methods for treating autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
AU2008352076A1 (en) * 2008-03-04 2009-09-11 Robert Rodriguez Modulation of enzymatic structure, activity, and/or expression level
WO2011143590A1 (en) * 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
US11208478B2 (en) * 2016-08-07 2021-12-28 The Wistar Institute Of Anatomy And Biology Methods of detecting and treating a tumor expressing pT346 PDK1
JP2020514349A (ja) * 2017-03-20 2020-05-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 癌の処置のための併用治療剤におけるａｐｅ１／ｒｅｆ−１阻害剤の使用
WO2019055525A1 (en) * 2017-09-12 2019-03-21 Raj Selvaraj FORMULATION OF SOLID NANOPARTICLES OF WATER-INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD CURING
EP3781148A4 (en) * 2018-04-16 2022-03-02 Rafael Pharmaceuticals, Inc. THERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER WITH 6,8-BIS-BENZYLTHIO-OCTONIC ACID
JP2021532134A (ja) * 2018-07-23 2021-11-25 ラファエル ファーマシューティカルズ， インコーポレイテッド ６，８−ビス（ベンジルスルファニル）オクタン酸を使用して膵臓癌を治療するための治療方法および組成物
MX2021007330A (es) * 2018-12-20 2021-09-30 National Univ Corporation Tokai National Higher Education And Research System Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
BR112021018138A2 (pt) * 2019-03-19 2021-11-16 Memorial Sloan Kettering Cancer Center Métodos terapêuticos e composições para tratar linfoma usando ácido 6,8-bis-benziltio-octanoico

Also Published As

Publication number Publication date
KR20210105913A (ko) 2021-08-27
EP3897606A4 (en) 2022-08-31
US20220040133A1 (en) 2022-02-10
CA3121645A1 (en) 2020-06-25
WO2020132401A1 (en) 2020-06-25
CN113543779A (zh) 2021-10-22
IL283609A (en) 2021-07-29
EP3897606A1 (en) 2021-10-27
AU2019405976A1 (en) 2021-06-24
JP2022514084A (ja) 2022-02-09
TW202038930A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
MX2021002322A (es) Nuevos metodos.
MX2021002321A (es) Nuevos metodos.
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
PH12020551425A1 (en) Rimegepant for cgrp related disorders
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
PH12014500386A1 (en) Combination treatment for hepatitis c
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MX2024002360A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
WO2020033838A3 (en) Treatment of egfr-mutant cancer
ZA202000028B (en) Use of vibegron to treat overactive bladder
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
BR112015012497A2 (pt) combinações farmacêuticas
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.